OGN vs. MDGL, BBIO, ALPN, NUVL, PRGO, ALKS, INSM, BPMC, CBAY, and BHVN
Should you be buying Organon & Co. stock or one of its competitors? The main competitors of Organon & Co. include Madrigal Pharmaceuticals (MDGL), BridgeBio Pharma (BBIO), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Perrigo (PRGO), Alkermes (ALKS), Insmed (INSM), Blueprint Medicines (BPMC), CymaBay Therapeutics (CBAY), and Biohaven (BHVN). These companies are all part of the "pharmaceutical preparations" industry.
Organon & Co. (NYSE:OGN) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, community ranking, media sentiment and institutional ownership.
77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 1.2% of Organon & Co. shares are owned by company insiders. Comparatively, 23.9% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Organon & Co. has a net margin of 16.33% compared to Madrigal Pharmaceuticals' net margin of 0.00%. Organon & Co.'s return on equity of -212.00% beat Madrigal Pharmaceuticals' return on equity.
Organon & Co. has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
Organon & Co. has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.47, meaning that its share price is 147% less volatile than the S&P 500.
Organon & Co. presently has a consensus target price of $21.80, suggesting a potential upside of 18.67%. Madrigal Pharmaceuticals has a consensus target price of $356.73, suggesting a potential upside of 66.73%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than Organon & Co..
In the previous week, Madrigal Pharmaceuticals had 2 more articles in the media than Organon & Co.. MarketBeat recorded 7 mentions for Madrigal Pharmaceuticals and 5 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.99 beat Madrigal Pharmaceuticals' score of 0.70 indicating that Organon & Co. is being referred to more favorably in the media.
Madrigal Pharmaceuticals received 432 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 68.56% of users gave Madrigal Pharmaceuticals an outperform vote while only 32.61% of users gave Organon & Co. an outperform vote.
Summary
Organon & Co. beats Madrigal Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Organon & Co. News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organon & Co. Competitors List
Related Companies and Tools
